These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9182350)

  • 1. [Implantable pacemaker-cardioverter-defibrillator. A cost-effective and life-prolonging treatment].
    Ohm OJ
    Tidsskr Nor Laegeforen; 1997 Apr; 117(9):1263-5. PubMed ID: 9182350
    [No Abstract]   [Full Text] [Related]  

  • 2. [Update on current care guidelines. Current care guideline: cardiac pacemaker therapy].
    Duodecim; 2010; 126(4):391-2. PubMed ID: 20486489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Technology under the skin].
    Wester K
    Tidsskr Nor Laegeforen; 1998 Sep; 118(21):3255. PubMed ID: 9772810
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe?
    Cowie MR
    Europace; 2009 Oct; 11(10):1407-8; author reply 1408-10. PubMed ID: 19684038
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sudden death prevention with implantable devices.
    Passman R; Kadish A
    Circulation; 2007 Jul; 116(5):561-71. PubMed ID: 17664385
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal complications of pacemaker and implantable cardioverter-defibrillator implantation: medical malpractice?
    Schulz N; Püschel K; Turk EE
    Interact Cardiovasc Thorac Surg; 2009 Apr; 8(4):444-8. PubMed ID: 19168462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implantable cardioverter-defibrillator: does everybody need one?
    Raj SR; Sheldon RS
    Prog Cardiovasc Dis; 2001; 44(3):169-94. PubMed ID: 11727276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chapter 10. Current evidence on the cost effectiveness of the implantable cardioverter defibrillator.
    O'Brien BJ; Yee R
    Can J Cardiol; 2000 Jun; 16 Suppl C():45C-7C. PubMed ID: 10887279
    [No Abstract]   [Full Text] [Related]  

  • 13. Should we afford implantable cardioverter defibrillator therapy?
    Camm AJ
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):59. PubMed ID: 16265354
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of implantable cardioverter-defibrillators.
    Boriani G; Biffi M; Martignani C; Gallina M; Branzi A
    Eur Heart J; 2001 Jun; 22(12):990-6. PubMed ID: 11428834
    [No Abstract]   [Full Text] [Related]  

  • 15. The implantable cardiac defibrillator: is the glass half empty or half full?
    de Lissovoy G
    Med Care; 2007 May; 45(5):371-3. PubMed ID: 17446821
    [No Abstract]   [Full Text] [Related]  

  • 16. Implantable cardioverter/defibrillator therapy: the meaning of terms.
    Smith ER
    Can J Cardiol; 2000 Oct; 16(10):1325-6. PubMed ID: 11064309
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Zwanziger J; Hall WJ; Dick AW; Zhao H; Mushlin AI; Hahn RM; Wang H; Andrews ML; Mooney C; Wang H; Moss AJ
    J Am Coll Cardiol; 2006 Jun; 47(11):2310-8. PubMed ID: 16750701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expenditure and value for money: the challenge of implantable cardioverter defibrillators.
    Boriani G; Biffi M; Martignani C; Diemberger I; Valzania C; Bertini M; Branzi A
    QJM; 2009 May; 102(5):349-56. PubMed ID: 19276209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter regarding article by Bokhari et al, "Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS)".
    Boriani G; Biffi M; Martignani C
    Circulation; 2005 Jan; 111(3):e26; author reply e26. PubMed ID: 15668348
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost advantage of different cardioverter-defibrillator devices.
    Veenhuyzen GD
    J Am Coll Cardiol; 2006 Jul; 48(2):418-9; author reply 419. PubMed ID: 16843205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.